Growth Hormone-Secreting Pituitary Adenoma

A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.

Also Known As:

Acromegaly Due To Pituitary Adenoma; GH-Secreting Pituitary Adenoma; Isolated Familial Somatotropinoma; Pituitary Adenoma, Growth Hormone-Secreting; Somatotrophinoma, Familial; Somatotropinoma, Familial Isolated; Adenoma, Somatotroph; Adenomas, Somatotroph; GH Secreting Pituitary Adenoma; GH-Secreting Pituitary Adenomas; Pituitary Adenoma, GH Secreting; Pituitary Adenoma, Growth Hormone Secreting; Pituitary Adenomas, GH-Secreting; Pituitary Growth Hormone Secreting Adenoma; Somatotroph Adenomas; Pituitary Adenoma, GH-Secreting; Pituitary Growth Hormone-Secreting Adenoma; Somatotroph Adenoma

Networked: 471 relevant articles (32 outcomes, 45 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Acromegaly
2.	Neoplasms (Cancer)
3.	Adenoma (Adenomas)
4.	Pituitary Neoplasms (Pituitary Adenoma)
5.	Carcinoid Tumor (Carcinoid)

Experts

1.	Melmed, Shlomo: 9 articles (01/2022 - 01/2000)
2.	Korbonits, Márta: 8 articles (11/2021 - 09/2003)
3.	Lee, Eun Jig: 8 articles (09/2021 - 01/2018)
4.	Bollerslev, Jens: 8 articles (07/2016 - 04/2008)
5.	Ku, Cheol Ryong: 7 articles (01/2021 - 01/2018)
6.	Yamada, Shozo: 7 articles (05/2016 - 04/2003)
7.	Brue, Thierry: 6 articles (11/2021 - 09/2007)
8.	Barlier, Anne: 6 articles (06/2021 - 10/2004)
9.	Zhang, Yazhuo: 6 articles (01/2021 - 05/2016)
10.	Xing, Bing: 6 articles (12/2020 - 02/2016)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Growth Hormone-Secreting Pituitary Adenoma:

1.	Growth Hormone (Somatotropin)IBA 10/01/2010 - "Using strict biochemical remission criteria, the authors assessed surgical outcomes after endoscopic transsphenoidal resection of growth hormone (GH)-secreting pituitary adenomas and identified preoperative factors that significantly influence the rate of remission. " 05/01/2009 - "We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors that significantly influence the remission. " 10/01/2010 - "The aim of this study was to determine the preoperative predictors of the extent of resection and endocrinological remission following endonasal endoscopic removal of growth hormone (GH)-secreting pituitary adenomas. " 02/01/2023 - "Endonasal resection is the first-line treatment for patients harboring growth hormone (GH)-secreting pituitary adenomas. " 02/01/2019 - "To investigate the clinical characteristics of delayed remission (DR) of growth hormone (GH)-secreting pituitary adenoma after transsphenoidal adenectomy and inform follow-up treatments. "
2.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 09/01/2013 - "Our study indicates that ESRP1 in somatotroph adenomas regulates transcripts that may be essential in the EMT progression and in the response to somatostatin analog treatment. " 12/01/1990 - "Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study." 01/01/2022 - "Somatotroph adenomas (SAs) exhibit a variable responsiveness to somatostatin analogue (SS-a) treatment, a process that is not well understood. " 01/01/2020 - "Is MRI follow-up relevant in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogues (SMSa)?" 11/01/2014 - "Before pregnancy three women had incomplete surgical resection of GH-secreting pituitary adenoma, all were treated with somatostatin analogues, and the medical treatment was withdrawal at the diagnosis of gestation. "
3.	pasireotideIBA 10/01/2019 - "Immunohistochemical expression level of SSTR5 and the granulation pattern of nine somatotroph adenomas were retrospectively determined to test for a correlation with the therapeutic efficacy of Pasireotide-LAR. " 04/01/2004 - "The higher number of responders of GH-secreting pituitary adenoma cultures to SOM230, compared with OCT, suggest that SOM230 has the potency to increase the number of acromegalic patients which can be biochemically controlled. " 04/01/2004 - "OCT (10 nM) significantly inhibited GH release in seven of nine GH-secreting pituitary adenoma cultures (range, -26 to -73%), SOM230 (10 nM) in eight of nine cultures (range, -22 to -68%), and SRIF-14 (10 nM) in six of six cultures (range, -30 to -75%). " 06/01/2022 - "Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal." 01/01/2022 - "Comment on "Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal"."
4.	Octreotide (Sandostatin)FDA LinkGeneric 01/01/2021 - "Combining four parameters, including diameter, Knosp grade, GH index and ∆GH% after octreotide treatment, we established a grading scale for predicting SG GH-secreting pituitary adenomas with an AUC of 0.84 and relatively high sensitivity and specificity. " 11/01/2013 - "We aimed to determine the expression of SSTRs 1, 2a, 3, and 5 in somatotroph adenomas, to correlate expression with clinical characteristics and the response to octreotide, and to ascertain whether preoperative octreotide treatment affected SSTR expression. " 09/01/2012 - "Ectopic growth hormone-secreting pituitary adenoma involving the clivus treated with octreotide: role of magnetic resonance imaging in the diagnosis and clinical follow-up." 01/01/2009 - "To elucidate factors influencing the acute effect of octreotide, we collected data from 56 patients with somatotroph adenoma from two institutions. " 03/01/2005 - "Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery."
5.	Glucose (Dextrose)FDA LinkGeneric 02/01/2016 - "Effect of Transsphenoidal Adenectomy on Glucose Tolerance Status in Patients with Growth Hormone-secreting Pituitary Adenoma." 01/01/2013 - "Patients with pure somatotroph adenomas are more likely than those with mixed adenomas to exhibit abnormal glucose metabolism." 01/01/2013 - "Importantly, patients with pure somatotroph adenomas were significantly more likely to present with abnormal glucose metabolism [48.7%] than those with mixed adenomas [9.7%] [p<0.001] independent of GH/IGF-1 levels or tumor invasiveness. " 01/01/2021 - "In the management of growth hormone (GH)-secreting pituitary adenomas, the oral glucose tolerance test (OGTT) has been the gold standard not only for diagnoses but also for the determination of biochemical remission. " 12/01/2002 - "The suppression of growth hormone (GH) to less than 1 microg/L during the oral glucose tolerance test (OGTT) is generally considered to be the standard for the assessment of biochemical remission of GH excess following surgery for GH-secreting pituitary adenomas. "
6.	Insulin-Like Growth Factor I (IGF-1)IBA 01/01/2021 - "A failure of GH suppression under 0.4 μg /L during an OGTT in patients with normalised IGF-1 and a higher Ki-67 index are independent predictors of recurrence after surgical remission in GH-secreting pituitary adenomas. " 01/01/2021 - "This study was designed to investigate microstructural pathology in the cortex and white matter in growth hormone-secreting pituitary adenoma, which characterized by excessive secretion of GH and IGF-1. " 05/01/1992 - "For comparison, the same studies were carried out on plasmas and somatotroph adenomas obtained from three other acromegalics (Cases 2-4) whose basal plasma GH and IGF-I levels were 22-45 ng/mL and 3.5-6.0 U/mL, respectively. " 01/01/2022 - "Growth hormone-secreting pituitary adenoma (GHPA) is an insidious disease with persistent hypersecretion of GH and IGF-1, causing increased morbidity and mortality. " 01/01/2019 - "BMD Z score was negatively correlated with disease duration and IGF-1 burden in patients with GH-secreting pituitary adenomas, and IGF-1 burden was an independent risk factor for reduced lumbar-spine BMD Z score."
7.	lanreotide (Somatuline)FDA Link 04/01/2003 - "A short administration of preoperative lanreotide 30 mg induced a statistically significant shrinkage of GH-secreting pituitary adenomas where this reduction was > 20% of the pretreatment value in 29% of the whole population. " 04/01/2003 - "Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage." 07/01/2003 - "This study was aimed to characterize the intracellular mechanisms mediating the in vitro antiproliferative and antisecretory effects of somatostatin and its analogue lanreotide, on primary cultures of GH-secreting pituitary adenoma cells. " 12/01/2004 - "Recent studies in molecular pathogenesis aiming to find novel therapy targets and reports on new pharmacological drugs effecting GH-secreting pituitary adenomas are reviewed (for example, lanreotide 60, SOM320 and pegvisomant). " 01/06/2014 - "Lanreotide ATG and octreotide LAR provide an effective medical treatment, whether as a primary or secondary therapy, for the treatment of GH-secreting pituitary adenoma; however, to maximize benefits with the least cost, several points should be emphasized before the application of SAs. "
8.	ProlactinIBA 10/01/2005 - "We investigated DA subtype 2 receptor (DR2) and SRIF receptor (sst) subtypes 2 and 5 expression in 25 GH-secreting pituitary adenomas and tested in primary culture the effects on GH and prolactin (PRL) secretion of sst agonists selectively interacting with sst2 (BIM-23120), sst5 (BIM-23206), and sst2 and sst5 (BIM-23244). " 01/01/2013 - "Pituitary histopathologic findings revealed pure GH-producing somatotroph adenomas (SA) in 147 patients, prolactin-production by mixed lactotroph (LA) and SA or mammosomatotroph adenoma (MSA) in 46 [22.4%], acidophil stem cell adenoma in 6 [2.9%], and other diagnoses in 6 [2.9%]. " 03/01/1979 - "Amongst the latter are included somatotroph adenomas, prolactin cell adenomas, melanocorticotroph adenomas and thyrotroph adenomas. " 01/01/2010 - "Double pituitary adenomas are rare occurrences in autoptical, surgical and neuroradiological series and are mostly due to non-functioning pituitary adenomas, GH-secreting and prolactin-secreting adenomas. " 04/24/2004 - "In three patients gynaecomastia was diagnosed: a 22-year-old man with concomitant thyrotoxicosis due to an extensively metastasized extragonadal choriocarcinoma, a 53-year-old man with hypogonadism due to Klinefelter's syndrome that was biochemically obscured due to medications leading to elevated prolactin levels, and a 62-year-old man with acromegaly and secondary hypogonadism due to a mixed prolactin and growth hormone secreting pituitary adenoma. "
9.	Adrenocorticotropic Hormone (ACTH)FDA Link 09/01/2001 - "The hyperplastic and adenomatous ACTH-immunoreactive cells were admixed with somatotroph adenoma cells. " 01/01/1996 - "There have been, to our knowledge, only five published reports on somatotroph adenomas accompanied by excessive ACTH secretion. " 01/01/1996 - "However, somatotroph adenomas showing hypersecretion of adrenocorticotropic hormone (ACTH) are extremely rare. " 01/01/2001 - "A marked decrease of p27 expression was noted in ACTH-secreting adenomas, 8/20 (40.0%), compared with other types of pituitary adenomas--GH-secreting adenomas, 35/46 (76.1%); PRL-secreting adenomas, 22/33 (66.7%); TSH-secreting adenomas, 8/11 (72.7%); and nonfunctioning adenomas, 55/69 (79.7%). " 11/01/2001 - "Silent mixed corticotroph and somatotroph adenomas are characterized by the following: no endocrine symptoms; presentation dominated by mass effect symptoms; macroadenoma presenting with acute pituitary hemorrhage; and production of both ACTH and GH."
10.	Sirolimus (Rapamycin)FDA Link 09/01/2009 - "The objective of the study was to evaluate the anti-proliferative efficacy of the mTOR inhibitor, rapamycin, and its orally bioavailable analog RAD001 on the GH-secreting pituitary tumor GH3 and MtT/S cells and in human GH-secreting pituitary adenomas (GH-omas) in primary cell cultures. "

Therapies and Procedures

1.	Therapeutics 04/01/2013 - "This is a retrospective, single-centre study of 52 patients with pathologically confirmed somatotroph adenoma who were naïve to medical therapy presenting between January 2001 and October 2010. " 09/01/2019 - "Therefore, T2-weighted sequences of pituitary MRI can help to classify GH-secreting pituitary adenomas into a T2-hypointense and T2-hyperintense type and, therefore, to identify patients who can better respond to first-line SSA therapy." 01/01/2017 - "To assess SSTR2 and SSTR5 expression in three groups of somatotroph adenomas: drug-naive, treated with long-acting (LA) SSA monotherapy, or LA-SSA/PEGV combination therapy before surgery. " 10/01/2015 - "Pituitary surgery is usually the first line therapy for GH secreting pituitary adenomas. " 10/01/2004 - "Despite important advances in human therapeutics, no specific treatment for both non-functioning gonadotroph and resistant somatotroph adenomas is available. "
2.	Radiotherapy 02/01/2005 - "The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas." 01/01/2016 - "The aim of the present study was to evaluate the safety and feasibility of hypofractionated stereotactic radiotherapy (SRT) with CyberKnife for growth hormone-secreting pituitary adenoma (GH-PA). " 01/01/2016 - "Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus." 01/01/2014 - "While it is likely that the described observations reflect the manifestations of a functional somatotroph adenoma in development, it is possible that pubertal growth, GH supplementation, its removal, or radiation therapy contributed to the described endocrine and pathologic changes." 07/01/2008 - "The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma."
3.	Hypophysectomy 11/02/2023 - "Transsphenoidal hypophysectomy for the treatment of hypersomatotropism secondary to a pituitary somatotroph adenoma in a dog." 12/11/2017 - "A cross-sectional study of patients who underwent hypophysectomy due to GH-secreting pituitary adenoma from April 2007 to December 2014 was carried out. " 05/01/2010 - "This is the first report detailing transsphenoidal hypophysectomy as a feasible and effective treatment for feline acromegaly due to a pituitary somatotroph adenoma. "
4.	Conformal Radiotherapy 07/15/2004 - "Stereotactic conformal radiotherapy is effective and safe in the treatment of GH-secreting pituitary adenoma to reduce hormonal overproduction and to improve local control. " 07/15/2004 - "Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma." 07/15/2004 - "To evaluate the reduction of hormonal overproduction and side effects as well as survival rates after fractionated stereotactic conformal radiotherapy (FSRT) and radiosurgery in patients with growth hormone (GH)-secreting pituitary adenoma. "
5.	Aftercare (After-Treatment) 01/01/2007 - "A 68-year-old woman presented with persistent acromegaly after treatment for a GH-secreting pituitary adenoma. " 05/01/1998 - "Ten patients with GH-secreting pituitary adenoma were studied before and 6 months after treatment with subcutaneous octreotide 0.2 to 0.6 mg/day. " 01/01/2007 - "Our aim was to investigate whether patients with documented GH-secreting pituitary adenomas leading to acromegaly would respond with attenuation of GH and insulin-like growth factor-1 (IGF-1) levels after treatment with a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist. "